192 related articles for article (PubMed ID: 22183619)
1. Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer.
Rowlands MA; Holly JM; Hamdy F; Phillips J; Goodwin L; Marsden G; Gunnell D; Donovan J; Neal DE; Martin RM
Cancer Causes Control; 2012 Feb; 23(2):347-54. PubMed ID: 22183619
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.
Roddam AW; Allen NE; Appleby P; Key TJ; Ferrucci L; Carter HB; Metter EJ; Chen C; Weiss NS; Fitzpatrick A; Hsing AW; Lacey JV; Helzlsouer K; Rinaldi S; Riboli E; Kaaks R; Janssen JA; Wildhagen MF; Schröder FH; Platz EA; Pollak M; Giovannucci E; Schaefer C; Quesenberry CP; Vogelman JH; Severi G; English DR; Giles GG; Stattin P; Hallmans G; Johansson M; Chan JM; Gann P; Oliver SE; Holly JM; Donovan J; Meyer F; Bairati I; Galan P
Ann Intern Med; 2008 Oct; 149(7):461-71, W83-8. PubMed ID: 18838726
[TBL] [Abstract][Full Text] [Related]
3. Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis.
Harrison S; Lennon R; Holly J; Higgins JPT; Gardner M; Perks C; Gaunt T; Tan V; Borwick C; Emmet P; Jeffreys M; Northstone K; Rinaldi S; Thomas S; Turner SD; Pease A; Vilenchick V; Martin RM; Lewis SJ
Cancer Causes Control; 2017 Jun; 28(6):497-528. PubMed ID: 28361446
[TBL] [Abstract][Full Text] [Related]
4. The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study.
Rowlands MA; Holly JM; Gunnell D; Gilbert R; Donovan J; Lane JA; Marsden G; Collin SM; Hamdy F; Neal DE; Martin RM
Cancer Causes Control; 2010 Nov; 21(11):1829-42. PubMed ID: 20652394
[TBL] [Abstract][Full Text] [Related]
5. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.
Young NJ; Metcalfe C; Gunnell D; Rowlands MA; Lane JA; Gilbert R; Avery KN; Davis M; Neal DE; Hamdy FC; Donovan J; Martin RM; Holly JM
Cancer Causes Control; 2012 Jun; 23(6):907-17. PubMed ID: 22527168
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
[TBL] [Abstract][Full Text] [Related]
7. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.
Mikami K; Ozasa K; Nakao M; Miki T; Hayashi K; Watanabe Y; Mori M; Sakauchi F; Washio M; Kubo T; Suzuki K; Wakai K; Nakachi K; Tajima K; Ito Y; Inaba Y; Tamakoshi A;
Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():57-61. PubMed ID: 20553083
[TBL] [Abstract][Full Text] [Related]
9. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.
Watts EL; Perez-Cornago A; Fensom GK; Smith-Byrne K; Noor U; Andrews CD; Gunter MJ; Holmes MV; Martin RM; Tsilidis KK; Albanes D; Barricarte A; Bueno-de-Mesquita HB; Cohn BA; Deschasaux-Tanguy M; Dimou NL; Ferrucci L; Flicker L; Freedman ND; Giles GG; Giovannucci EL; Haiman CA; Hankey GJ; Holly JMP; Huang J; Huang WY; Hurwitz LM; Kaaks R; Kubo T; Le Marchand L; MacInnis RJ; Männistö S; Metter EJ; Mikami K; Mucci LA; Olsen AW; Ozasa K; Palli D; Penney KL; Platz EA; Pollak MN; Roobol MJ; Schaefer CA; Schenk JM; Stattin P; Tamakoshi A; Thysell E; Tsai CJ; Touvier M; Van Den Eeden SK; Weiderpass E; Weinstein SJ; Wilkens LR; Yeap BB; ; Allen NE; Key TJ; Travis RC
Int J Epidemiol; 2023 Feb; 52(1):71-86. PubMed ID: 35726641
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
[TBL] [Abstract][Full Text] [Related]
11. Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.
Bonilla C; Lewis SJ; Rowlands MA; Gaunt TR; Davey Smith G; Gunnell D; Palmer T; Donovan JL; Hamdy FC; Neal DE; Eeles R; Easton D; Kote-Jarai Z; Al Olama AA; Benlloch S; Muir K; Giles GG; Wiklund F; Grönberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Pashayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park J; Kaneva R; Batra J; Teixeira MR; Pandha H; ; Lathrop M; Martin RM; Holly JM
Int J Cancer; 2016 Oct; 139(7):1520-33. PubMed ID: 27225428
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study.
Rowlands MA; Tilling K; Holly JM; Metcalfe C; Gunnell D; Lane A; Davis M; Donovan J; Hamdy F; Neal DE; Martin RM
Cancer Causes Control; 2013 Jan; 24(1):39-45. PubMed ID: 23085814
[TBL] [Abstract][Full Text] [Related]
13. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
14. Associations of childhood and adulthood height and the components of height with insulin-like growth factor levels in adulthood: a 65-year follow-up of the Boyd Orr cohort.
Bray I; Gunnell D; Holly JM; Middleton N; Davey Smith G; Martin RM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1382-9. PubMed ID: 16434460
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen.
Kanety H; Madjar Y; Dagan Y; Levi J; Papa MZ; Pariente C; Goldwasser B; Karasik A
J Clin Endocrinol Metab; 1993 Jul; 77(1):229-33. PubMed ID: 7686915
[TBL] [Abstract][Full Text] [Related]
17. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
18. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.
Rowlands MA; Holly JM; Gunnell D; Donovan J; Lane JA; Hamdy F; Neal DE; Oliver S; Smith GD; Martin RM
Cancer Res; 2012 Jan; 72(2):503-15. PubMed ID: 22106399
[TBL] [Abstract][Full Text] [Related]
19. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.
Le H; Arnold JT; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E952-60. PubMed ID: 16368782
[TBL] [Abstract][Full Text] [Related]
20. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.
Watts EL; Perez-Cornago A; Appleby PN; Albanes D; Ardanaz E; Black A; Bueno-de-Mesquita HB; Chan JM; Chen C; Chubb SAP; Cook MB; Deschasaux M; Donovan JL; English DR; Flicker L; Freedman ND; Galan P; Giles GG; Giovannucci EL; Gunter MJ; Habel LA; Häggström C; Haiman C; Hamdy FC; Hercberg S; Holly JM; Huang J; Huang WY; Johansson M; Kaaks R; Kubo T; Lane JA; Layne TM; Le Marchand L; Martin RM; Metter EJ; Mikami K; Milne RL; Morris HA; Mucci LA; Neal DE; Neuhouser ML; Oliver SE; Overvad K; Ozasa K; Pala V; Pernar CH; Pollak M; Rowlands MA; Schaefer CA; Schenk JM; Stattin P; Tamakoshi A; Thysell E; Touvier M; Trichopoulou A; Tsilidis KK; Van Den Eeden SK; Weinstein SJ; Wilkens L; Yeap BB; Key TJ; Allen NE; Travis RC
Int J Cancer; 2019 Dec; 145(12):3244-3256. PubMed ID: 30873591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
